New Generic Crestor And Its Relation To A Crestor Lawsuit
In August, 2011, the Food and Drug Administration (FDA) approved a generic form of Crestor in 5, 10, 20, and 40 mg doses. Watson Pharmaceuticals, Inc., the manufacturer of the new generic drug, will market the drug under the name rosuvastatin zinc, as opposed to AstraZeneca’s rosuvastatin calcium. On July 15, 2010, Watson Laboratories, Inc., a subsidiary of Watson Pharmaceuticals, Inc., filed a New Drug Application (NDA) in order to gain the approval. A few months later, AstraZeneca filed a lawsuit in US District Court that prevented the FDA’s final approval of the generic drug and would prevent Watson from selling the generic drug until April 1, 2013, or until the lawsuit was resolved in court, depending on which happens first. No further updates are available.
Generic Crestor Side Effects
There seems to be nothing published yet concerning the side effects of generic Crestor. However, AstraZeneca’s original brand name Crestor has come under scrutiny and litigation regarding a number of its side effects. The Crestor side effects that are most concerning are cardiomyopathy, as well as the potential for skeletal muscle damage and the kidney damage that may result from the breakdown of muscle causing rhabdomyolysis.
Crestor Side Effects
Patients using Crestor are seventy five times more likely to experience kidney-related problems while taking the drug than they are when not taking the drug. These kidney problems are actually a secondary side effect caused by rhabdomyolysis, which is a serious disease that may cripple, or even kill, the people who experience its symptoms. Rhabdomyolysis is a disease of the skeletal muscles characterized by the death of a large number of muscle cells simultaneously, or within a short period of time. When muscle cells die, they release their proteins. These proteins are picked up by the blood stream and travel throughout the body until they reach the kidneys. The kidneys are part of one of the body’s natural filtering systems. When this excess of protein from the dead skeletal muscle cells reaches the kidneys, the filtering mechanisms become blocked by the protein and they are trapped in the kidneys. Sometimes, the result is kidney failure.
Skeletal muscle cells also contain a high level of potassium. When the potassium is released into the blood stream, it will travel to the heart and can possibly cause malignant heart arrhythmia or cardiac arrest (heart attack).
More than one Crestor lawyer may be wondering how the release of a generic form of Crestor will affect their Crestor lawsuits. At this point, it is really difficult to say. AstraZeneca’s lawsuit against Watson Laboratories, Inc. stopped the FDA’s approval process, and has stopped the flow of information about the new generic drug, including its side effects. If the generic form of Crestor presents the same side effects as the original Crestor, more lawsuits may be the result.